185 related articles for article (PubMed ID: 12036381)
1. A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment.
Veenstra DL; Ramsey SD; Sullivan SD
Pharmacoeconomics; 2002; 20 Suppl 1():21-30. PubMed ID: 12036381
[TBL] [Abstract][Full Text] [Related]
2. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.
Nichol MB; Knight TK; Epstein J; Honda DH; Tretiak R
J Manag Care Pharm; 2007 May; 13(4):360-71. PubMed ID: 17506602
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomics and formulary decision making.
Sanchez LA
Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
[TBL] [Abstract][Full Text] [Related]
5. Application of pharmacoeconomics to formulary decision making in managed care organizations.
Suh DC; Okpara IR; Agnese WB; Toscani M
Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
[TBL] [Abstract][Full Text] [Related]
6. Managing the continuum of treatment: modeling the economic impact of treating diabetes.
Brixner DI
J Manag Care Pharm; 2005 Aug; 11(6 Suppl B):S19-22. PubMed ID: 23570226
[TBL] [Abstract][Full Text] [Related]
7. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.
Fry RN; Avey SG; Sullivan SD
Value Health; 2003; 6(5):505-21. PubMed ID: 14627057
[TBL] [Abstract][Full Text] [Related]
8. Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies.
Vondeling H; Iversen PB
Eur J Health Econ; 2004 Oct; 5(3):263-9. PubMed ID: 15714347
[TBL] [Abstract][Full Text] [Related]
9. The arrival of economic evidence in managed care formulary decisions: the unsolicited request process.
Neumann PJ
Med Care; 2005 Jul; 43(7 Suppl):27-32. PubMed ID: 16056006
[TBL] [Abstract][Full Text] [Related]
10. Economic implications with newer agents to reduce cardiovascular risk in diabetes.
McAdam-Marx C
Am J Manag Care; 2018 Aug; 24(13 Suppl):S279-S285. PubMed ID: 30160395
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic Evaluations: Guidelines for Drug Purchasers.
Langley PC; Sullivan SD
J Manag Care Spec Pharm; 2020 Jun; 26(6):689-695. PubMed ID: 32463775
[TBL] [Abstract][Full Text] [Related]
12. Use of pharmacoeconomic data in making hospital formulary decisions.
Odedina FT; Sullivan J; Nash R; Clemmons CD
Am J Health Syst Pharm; 2002 Aug; 59(15):1441-4. PubMed ID: 12166044
[TBL] [Abstract][Full Text] [Related]
13. Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making.
Mullins CD; Wang J
Pharmacoeconomics; 2002; 20(1):9-21. PubMed ID: 11817989
[TBL] [Abstract][Full Text] [Related]
14. The role of pharmacoeconomics in disease management. A pharmaceutical benefit management company perspective.
Thomas N
Pharmacoeconomics; 1996; 9 Suppl 1():9-15. PubMed ID: 10160115
[TBL] [Abstract][Full Text] [Related]
15. Managed care guidelines for the economic evaluation of pharmaceuticals.
Langley PC; Martin RE
Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
[TBL] [Abstract][Full Text] [Related]
16. Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study.
Hung A; Slejko JF; Lugo A; Shaya F; Haines ST; Mullins CD
J Manag Care Spec Pharm; 2019 Aug; 25(8):913-921. PubMed ID: 31347981
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis and the formulary decision-making process.
Wang Z; Salmon JW; Walton SM
J Manag Care Pharm; 2004; 10(1):48-59. PubMed ID: 14720105
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomics: a managed care perspective.
Clouse JC
Top Hosp Pharm Manage; 1994 Jan; 13(4):54-9. PubMed ID: 10130684
[TBL] [Abstract][Full Text] [Related]
19. Formularies, therapeutics, and outcomes: new opportunities.
Fullerton DS; Atherly DS
Med Care; 2004 Apr; 42(4 Suppl):III39-44. PubMed ID: 15026670
[TBL] [Abstract][Full Text] [Related]
20. Long-term consequences of type 2 diabetes mellitus: economic impact on society and managed care.
Killilea T
Am J Manag Care; 2002 Oct; 8(16 Suppl):S441-9. PubMed ID: 12408407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
